Branebrutinib (BMS-986195)
CAS: 1912445-55-6
Ref. 3D-MBD44555
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued |
Product Information
Branebrutinib is a reversible covalent inhibitor of the fibrinogen-degrading enzyme, plasmin. It is used for the treatment of pemphigoid and other autoimmune diseases. The drug binds to the active site of plasmin, irreversibly blocking its access to fibrinogen and inhibiting the degradation of fibrinogen. In animal models, branebrutinib has been shown to be effective in treating collagen-induced arthritis and experimental allergic encephalomyelitis, two animal models for human autoimmune diseases. Branebrutinib has also been shown to have a pharmacokinetic profile that is sufficiently long in duration to allow once daily dosing and a pharmacodynamic profile that leads to inhibition of platelet aggregation at concentrations below those required for inhibition of neutrophil function. A dose-response study was conducted on healthy volunteers who were given single doses up to 1000 mg. The study found that the effective
